Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments. (Formula I)
1. A method of inhibiting or relieving cancer in a patient, which method comprises administering to said patient a therapeutically effective amount of a Compound: that is:
or a single isomer thereof; in combination with one or more chemotherapeutic agents.
2. The method of claim 1 where the cancer is selected from breast cancer, colon cancer, rectal cancer, endometrial cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, glioblastoma, hepatocellular carcinoma, small cell lung cancer, non-small cell lung cancer, melanoma, ovarian cancer, cervical cancer, pancreatic cancer, prostate carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, and thyroid carcinoma.
3. The method of claim 1 or 2 where the treatment one or more chemotherapeutic agents is independently selected from the group consisting of rapamycin, a rapamycin analogue, an alkylating agent a taxane, a platin, an EGFR inhibitor, and an ErbB2 inhibitor.
4. The method of claim 3 where the one or more chemotherapeutic agents is independently selected from rapamycin, paclitaxel, carboplatin, lapatinib, and erlotinib.
5. The method of claim 1 or 2 wherein the chemotherapeutic agent is erlotinib.
6. The method of claim 1 or 2 wherein the chemotherapeutic agent is lapatinib.
7. The method of claim 1 or 2 wherein the chemotherapeutic agent is carboplatin.
8. The method of claim 1 or 2 wherein the chemotherapeutic agent is paclitaxel.
9. The method of claim 1 or 2 wherein the chemotherapeutic agent is rapamycin.